Special Issue "Nanoparticle-Based Vaccines against Chronic Inflammatory Diseases"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 100

Special Issue Editor

Sharjah Institute of Medical Research, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates
Interests: immunology; chronic inflammation; Asthma; nanoparticles; vaccine development

Special Issue Information

Dear Colleagues,

For the past few years, the scientific and medical communities have reported the use of nanotechnology, nanomedicine, and vaccines on the improved management of chronic inflammatory diseases. Vaccination has proven to be a powerful tool to reduce the burden of infectious diseases in patients with chronic inflammatory diseases and holds the potential to be used as a therapeutic strategy for them.

Chronic inflammatory diseases leading to target tissue destruction and disability not only cause the increase in patients' pain but also contribute to a huge economic burden for society. Nanomedicine can be developed through encapsulation of drug into nanoparticles, conjugation of specific targeting ligand on nanoparticles, and chemical and physical interaction with multifunction properties would allow for effective therapy at the early stage of diseases.

In spite of recent novel successes in vaccine development, vaccines to treat chronic inflammatory diseases remain an unmet need. Emerging nanoparticle-based vaccines as a new-generation strategy can be a potential alternative to conventional vaccines.

In this Special Issue, papers which discuss multiple nanoparticles with a focus on their potential in treatment of chronic inflammatory diseases and the development and advances in nanoparticle-based vaccines against chronic inflammatory conditions are welcome.

Prof. Dr. Rabih Halwani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nanoparticles
  • vaccine
  • conjugate vaccines
  • vaccine development
  • drug delivery
  • chronic inflammation
  • T cell
  • antibody-nanocarrier

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop